Vedanta's microbiome therapy for IBD disappoints Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce.

While #VedantaBiosciences waits for a phase 3 readout for its lead #microbiome therapy based on live bacteria, an earlier-stage programme has failed a mid-stage #trial.

pharmaphorum.com/news/vedanta...

Vedanta Biosciences reveals Phase 2 VE303 results - PharmaTimes Study highlights VE303's potential in reducing recurrent CDI

#gastroenterology #VedantaBiosciences #VE303 #recurrentCDI #Phase2CONSORTIUMstudy #recurrentClostridioidesdifficileinfection #rCDI #rCDIprevention #CDIrecurrence #VE303organisms #VE303mechanisms #microbiomerestoration #microbiome #RESTORATiVE303 #CDIresistance
pharmatimes.com/news/vedanta...